Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) EBITDA Margin (2019 - 2025)

Burning Rock Biotech has reported EBITDA Margin over the past 7 years, most recently at 13.8% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 4594.0% year-over-year to 13.8%; the TTM value through Dec 2025 reached 11.04%, up 5523.0%, while the annual FY2025 figure was 11.02%, 5551.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 13.8% at Burning Rock Biotech, up from 14.05% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 6.69% in Q2 2025 and troughed at 195.13% in Q1 2022.
  • A 5-year average of 105.84% and a median of 131.87% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: tumbled -11890bps in 2021 and later soared 10774bps in 2024.
  • Year by year, EBITDA Margin stood at 187.22% in 2021, then increased by 17bps to 156.21% in 2022, then increased by 13bps to 136.47% in 2023, then skyrocketed by 56bps to 59.74% in 2024, then skyrocketed by 77bps to 13.8% in 2025.
  • Business Quant data shows EBITDA Margin for BNR at 13.8% in Q4 2025, 14.05% in Q3 2025, and 6.69% in Q2 2025.